<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04082507</url>
  </required_header>
  <id_info>
    <org_study_id>AFP_AP</org_study_id>
    <nct_id>NCT04082507</nct_id>
  </id_info>
  <brief_title>Maternal Serum Alpha-fetoprotein Level May Predict the Presence of Morbid Adherent Placenta</brief_title>
  <official_title>Alpha-fetoprotein as a Biochemical Marker in Prediction of Placenta Acreta Increta Percreta</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>rasha medhat abdul-hady</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare between alpha-fetoproteine as a biological marker and
      between ultrasound and Doppler in prediction of morbid adherent placenta.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      in pregnant women withe previous cesarean section, placenta previa and ultrasonographic
      finding of an abnormally adherent placenta dose maternal serum alpha-fetoprotein predict
      prenataly the presence of morbid adherent placenta accurately?
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">August 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Maternal serum alpha-fetoprotein</measure>
    <time_frame>From 28weeks to 37 weeks</time_frame>
    <description>ng/ml or MOM(Multiple of the median)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Placenta Accreta</condition>
  <arm_group>
    <arm_group_label>Non_adherent plcenta</arm_group_label>
    <description>placenta separated within 15 minutes after delivery of fetus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adherent placenta</arm_group_label>
    <description>placenta dosenot separated within 15 minutes after delivery of fetus</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Serum alpha-fetoproteine</intervention_name>
    <description>Midtrimesteric serum alpha-fetoprotein mesurment with 2D US and 3D power Doppler with MS US scan .</description>
    <arm_group_label>Adherent placenta</arm_group_label>
    <other_name>2D Ultrasound</other_name>
    <other_name>3D power doppler with MS US</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        150 pregnant women from 28wk to full term who are attending outpatient clinic and emergency
        room ain shams university maternal hospital
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pregnant women with history of scarred uterus

               -  plcenta previa covering the scar of previous caesarean section as diagnosed by
                  2DU/S

               -  Gestational age from 28wks to full term

        Exclusion Criteria:

          -  pregnant women with fetus with congenital anomalies

               -  pregnant women with ovarian swelling

               -  pregnant women with medical disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ain shams university maternity hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 29, 2019</study_first_submitted>
  <study_first_submitted_qc>September 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2019</study_first_posted>
  <last_update_submitted>September 6, 2019</last_update_submitted>
  <last_update_submitted_qc>September 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>rasha medhat abdul-hady</investigator_full_name>
    <investigator_title>Lecturer of obstetrics and gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Placenta Accreta</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

